SNMMI and editors of The Journal of Nuclear Medicine (JNM) announced on June 28 that the publication had achieved the highest impact factor in its history, ranking fourth among all medical imaging journals, according to new data released in the 2021 Journal Citation Reports. “This continued rise in visibility emphasizes not only the high quality of the journal but also the rise in importance of nuclear medicine as a whole,” said JNM editor-in-chief Johannes Czernin, MD. “Revolutionary advances in nuclear medicine research are resulting in revolutionary care for patients.”
JNM’s impact factor increased more than 10% over last year, from 10.057 (2020) to 11.082 (2021). With 35,215 total citations, the journal was fourth in impact factor and third in Journal Citation Indicator among 200 journals in the medical imaging category. JNM’s total citations increased by 7%, and its 5-year impact factor increased almost 15%. Among nuclear medicine journals, JNM continues to have the highest impact factor, total citations, 5-year impact factor, Eigenfactor and normalized Eigenfactor scores, and article influence score.
“This is a tribute to the contributions of diverse scientists from all areas of the field, from advances in imaging instrumentation to important aspects of theranostic and therapeutic approaches,” said Czernin. JNM has highlighted some of those advances in recent supplements focused on personalized dosimetry for cancer therapy, nuclear endocrinology, and molecular imaging of neurodegeneration.
The impact factor is a quantitative measure of the frequency with which an article in a journal is cited. It is used as a measure of the overall influence of a journal within scientific, professional, and academic communities. “I am grateful for the support of SNMMI and its Publications Committee, the valuable contributions of our staff, the vital input from our editorial board and reviewers, and the dedication and expertise of the team of associate editors whose work made this success possible,” said Czernin.
SNMMI
- © 2022 by the Society of Nuclear Medicine and Molecular Imaging.